We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

Pharmacogenomics Market - Size, Share, Trends, and Forecast to 2027

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application) was valued at US$ 8,357.3 million in 2017 and is projected to expand at a CAGR of 10.8% during the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights. Advancements in technology, increasing developments by key players, rising prevalence of lifestyle related diseases are expected to contribute to meteoric growth of the pharmacogenomics market over the forecast period.

Increasing engagement of pharmaceutical companies in pharmacogenomics is increasing potential opportunities for various phases of drug discovery and development processes. In parallel with rapid advancements in the identification and mapping of Single Nucleotide Polymorphism (SNPs) across the human genome, technological discoveries and enhancements to high-throughput genotyping have also made significant strides. Leading biotech firms have driven genotyping throughput to scales and significantly driving down costs. Pharmacogenomics initiatives have led to new discoveries and development of several treatments that are tailored for specific characteristics such as genetic makeup or genetic profile of an individual tumor, that helps transform the treatment methods. Increasing government funding to help companies develop bioinformatics technology for precision medicine research applications. For instance, in 2017, Armonica Technologies, Inc., an Albuquerque-based company received US$1.5 million from the government's US $40 million catalyst fund. This fund is intended for seed early-stage companies in New Mexico that are involved in developing novel technologies.

In therapeutic application, oncology portfolio is of strategic importance for researchers to develop more targeted approaches for the treatment of cancer. For an instance, AstraZeneca oncology portfolio will increasingly rely on the use of genetics and genomics for patient identification and stratification, which in turn, provides a source of novel biomarkers and diagnostics. This allows them to streamline the R&D process and help to better understand the biological basis of the diseases that are aiming to be treated. Thus, integration of pharmacogenomics analysis results in increased designing of tailored drugs, which is expected to increase profits for drug manufacturers.

Browse 28 Market Data Tables and 31 Figures spread through 160 Pages and in-depth TOC on "" Pharmacogenomics Market, by Technology Type (Polymerase Chain Reaction, Sequencing, Microarray, and Other Technologies), and by Application (Drug Discovery and Therapeutic Application), and by Region - Global Forecast to 2026""

To know the latest trends and insights related to pharmacogenomics market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pharmacogenomics-market-1053

North America is expected to witness highest growth in the global pharmacogenomics market, owing to increasing number of clinical trials for various application areas and rising biotechnology and life sciences sector in this region as well as the increasing focus on research and development by the top market players in these regions. North America is followed by Asia Pacific with the second highest growth rate during the forecast period. For instance, Thermo Fisher Scientific, in 2017, announced an Asia Precision Medicine research array for regional screening initiatives, which has reduced costs and complexity of analysis associated with whole genome sequencing to help the research of diseases among people living in Asia, which in turn, is expected to favor growth of the market in Asia Pacific.

The healthcare facilities and services in the Middle Eastern countries are underdeveloped, however, have high potential to grow in the near future. To accomplish the goal, the Middle Eastern countries are forming alliances with global leading companies as well as government organizations to foster the development of healthcare in these countries. For instance, in 2016, Middle East Medical Assembly at American University of Beirut (AUB) explored precision medicine sector, which is expected to revolutionize the healthcare and disease treatment in the Middle East, as MEMA brings physicians and experts together to discuss the latest challenges and novelties in precision medicine and genomics.

Vendors are continuously investing in the development of the pharmacogenomics for various applications in clinical and translational research to find a solution to the problems of under-served patients, misdiagnoses, adverse drug reactions (ADRs), and ineffective therapeutics, which is projected to provide lucrative growth over the forecast period. In May 2015, Rosetta Genomics Ltd. launched OncoGxOne, Admera Health's next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer, to provide clear, concise, and actionable clinical recommendations from a single, comprehensive test.

Key Takeaways of the Pharmacogenomics Market:

The global pharmacogenomics market is expected to expand at a CAGR of 8% during the forecast period (2018-2026), due to foster collaborations among the pharmaceutical industry, academic researchers, regulators and government organizations across various regions
Increasing demand for sequencing, owing to its wide application in cancer pharmacogenetic and ability to sequence large number of genes up to the complete genome in a single reaction.
Sequencing is expected to show a meteoric growth over the forecast period, as growing awareness among federal agencies, such as the FDA and NIH, in advancing NGS research and development relevant to pharmacogenetics for personalized medicine raising the requirement in the public and private sectors
Among applications, drug discovery is the fastest growing segment, as this is an emerging field and there are currently a large number of pharmacogenomics tests to detect mutations in the genes responsible for various infectious and non-infectious diseases
Some of the major players involved in global pharmacogenomics market are Thermo Fisher Scientific Inc., Abbott Laboratories, F. Hoffmann-La Roche AG, Qiagen N.V., Pacific Biosciences of California, Inc., Diatech Pharmacogenetics Srl and Assurex Health Inc.



Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved